Gujarat Themis Biosyn Limited Q1 FY26 results deck summary

Results deck of 1 Aug 2025, summarised by AI from the filing.

Q1 FY26 revenue ₹35.87 cr, EBITDA ₹13.91 cr and PAT ₹9.05 cr, hit by one-off legal and GST expenses; new fermentation unit expected by end of calendar year.

Key takeaways

1. Fermentation unit New fermentation unit expected to be completed by end of this calendar year.
2. API unit New API unit operational; production began May 2025 and validation batches in progress.
3. Forward integration Will offer synthetic and fermentation-based APIs, targeting export markets such as US and Europe.
4. One-off impacts Inventory volatility and April power failure hampered production; legal and GST expenses impacted margins.

Original filing on BSE

Gujarat Themis Biosyn Limited Q1 FY27 results

As filed: Revenue ₹43.8 cr (+22% year on year), EBITDA ₹20.8 cr (+49% year on year), PAT ₹11.1 cr (+23% year on year), EBITDA margin 47.5% (+861 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹44.2 cr (+16% year on year), EBITDA ₹19.4 cr (+21% year on year), PAT ₹10.9 cr (−9% year on year), EBITDA margin 43.8% (+169 bps). Score 55 of 100, In line with trend. EBITDA margin rose 169 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 13% from last quarter. Share price after the results: +8.8% in 30 days (Nifty 500: +2.1%).
• Q3 FY26: Revenue ₹43.4 cr, EBITDA ₹21.3 cr, PAT ₹12.5 cr, EBITDA margin 49.1%. Not scored. No result for the same quarter last year. Share price after the results: −9.3% in 29 days (Nifty 500: −4.0%).
• Q2 FY26: Revenue ₹42.0 cr, EBITDA ₹21.0 cr, PAT ₹14.0 cr, EBITDA margin 50.0%. Not scored. No result for the same quarter last year. Share price after the results: −14.8% in 30 days (Nifty 500: −0.5%).
• Q1 FY26: Revenue ₹36.0 cr, EBITDA ₹14.0 cr, PAT ₹9.0 cr, EBITDA margin 38.9%. Not scored. No result for the same quarter last year. Share price after the results: −3.2% in 28 days (Nifty 500: −2.0%).
• Q4 FY25: Revenue ₹38.0 cr, EBITDA ₹16.0 cr, PAT ₹12.0 cr, EBITDA margin 42.1%. Not scored. No result for the same quarter last year. Share price after the results: −3.3% in 30 days (Nifty 500: +0.8%).

Past price moves after results do not indicate future moves. Not a recommendation.

Gujarat Themis Biosyn Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Earnings call (10 Aug 2026), Results deck (7 Aug 2026)
• Q4 FY26: Results deck (25 May 2026)
• Q3 FY26: Results deck (5 Feb 2026)
• Q2 FY26: Results deck (10 Nov 2025)
• Q1 FY26: Results deck (1 Aug 2025)
• Q4 FY25: Results deck (20 May 2025)
• Other events: Strategy deck (29 Jun 2026), Strategy deck (22 May 2026), Strategy deck (23 Apr 2026)